Learning is reinforced via application of modelling and simulation skills to real pharmacokinetic and pharmacodynamic data. The course has been developed with an emphasis on mechanistic approaches to ...

Rani Therapeutics (RANI) announced pharmacokinetic and pharmacodynamic data from a preclinical study evaluating RT-114, a GLP-1/GLP-2 dual ...

Learning is reinforced via application of modelling and simulation skills to real pharmacokinetic and pharmacodynamic data. The course has been developed with an emphasis on mechanistic approaches to ...

Blood samples were collected serially from 0 to 16 hours. Noncompartmental methods were used to determine pharmacokinetic parameters. Results: Maximum plasma concentrations were 3.69 and 3.38 μg ...

Quantification and prediction of human fetal (-)-Δ 9-tetrahydrocannabinol/(±)-11-OH-Δ 9-tetrahydrocannabinol exposure during pregnancy to inform fetal cannabis ...

Purpose Pharmacokinetic considerations in patients who have undergone Roux-en-Y gastric bypass (RYGB) are explored. Summary The prevalence of obesity, especially morbid obesity, has dramatically ...

announced today that a new human pharmacokinetic (PK) data abstract was presented at the Society of Surgical Oncology (SSO) 2025 Annual Meeting on March 27 – 29, 2025 in Tampa, FL: ePoster P379.

Lexaria Bioscience (LEXX) announced pharmacokinetic results from Human Study #3 or GLP-1-H24-3, comparing an oral version of ...

The most common TRAEs were Grade 1 diarrhea (N=4), Grade 1 nausea (N=2) and Grade 1 pruritus (N=2). Pharmacokinetic and Selectivity Profile OKI-219 has shown favorable PK data that support ...

RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared ...

Alzamend Neuro Inc. recently presented pharmacokinetic data for the lithium-based sparing therapy AL-001, a lithium salicylate/L-proline co-crystal, in 5XFAD mice, a murine model of Alzheimer’s ...

The data indicated safety, tolerability, and pharmacokinetic and pharmacodynamic profiles that support further development of VG-3927 as a once-daily oral therapy for AD. The Watertown ...